- Home
- CANF vs MMA Comparison
CANF vs MMA Comparison
Compare CANF & MMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MMA
- Stock Information
- Founded
- CANF 1994
- MMA 2013
- Country
- CANF Israel
- MMA Australia
- Employees
- CANF N/A
- MMA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MMA
- Sector
- CANF Health Care
- MMA
- Exchange
- CANF Nasdaq
- MMA Nasdaq
- Market Cap
- CANF 14.8M
- MMA 13.4M
- IPO Year
- CANF N/A
- MMA 2024
- Fundamental
- Price
- CANF $1.03
- MMA $1.40
- Analyst Decision
- CANF Strong Buy
- MMA
- Analyst Count
- CANF 2
- MMA 0
- Target Price
- CANF $14.00
- MMA N/A
- AVG Volume (30 Days)
- CANF 129.3K
- MMA 426.1K
- Earning Date
- CANF 04-14-2025
- MMA 01-21-2025
- Dividend Yield
- CANF N/A
- MMA N/A
- EPS Growth
- CANF N/A
- MMA N/A
- EPS
- CANF N/A
- MMA N/A
- Revenue
- CANF $674,000.00
- MMA $407,412.00
- Revenue This Year
- CANF $461.72
- MMA N/A
- Revenue Next Year
- CANF N/A
- MMA N/A
- P/E Ratio
- CANF N/A
- MMA N/A
- Revenue Growth
- CANF N/A
- MMA N/A
- 52 Week Low
- CANF $0.98
- MMA $0.60
- 52 Week High
- CANF $4.69
- MMA $4.11
- Technical
- Relative Strength Index (RSI)
- CANF 39.89
- MMA N/A
- Support Level
- CANF $1.02
- MMA N/A
- Resistance Level
- CANF $1.09
- MMA N/A
- Average True Range (ATR)
- CANF 0.04
- MMA 0.00
- MACD
- CANF -0.00
- MMA 0.00
- Stochastic Oscillator
- CANF 6.67
- MMA 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MMA Alta Global Group Limited
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.